Brief: Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F
21/12/2023 12:19
Dec 21 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES ANNOUNCES CHINA NMPA CLEARANCE FOR
IND
APPLICATION FOR PHASE 1/2 CLINICAL TRIAL OF FASTCAR-T GC012F FOR
THE TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
* GRACELL BIOTECHNOLOGIES INC- FASTCAR-T GC012F HAS
DEMONSTRATED A
FAVORABLE SAFETY PROFILE IN CLINICAL INVESTIGATOR-INITIATED
TRIALS
* GRACELL BIOTECHNOLOGIES INC- COMPANY WILL ALSO COMMENCE
PHASE
1/2 CLINICAL STUDY IN U.S. AN IIT IS UNDERWAY TO EVALUATE GC012F
FOR TREATMENT OF RSLE
Source text for Eikon: ID:nGNXbhhHmk
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27